The use of topical rapamycin in the treatment of superficial lymphatic malformations

Publication date: Available online 5 October 2018

Source: Journal of the American Academy of Dermatology

Author(s): Pablo García Montero, Javier del Boz, Eulalia Baselga Torres, José Manuel Azaña Defez, Manuel Alcaraz Vera, Jesús Tercedor Sánchez, Lucero Noguera Morel, Ángel Vera Casaño

Abstract

Background

The superficial lymphatic component of vascular malformations poses a significant treatment challenge. It is responsible for the majority of symptoms presented and to date there is no consensus regarding treatment.

Objective

To evaluate the effectiveness of topical rapamycin in treating superficial lymphatic malformations (LM).

Methods

A case series study was performed of patients with superficial LM, treated with topical rapamycin. The clinical characteristics of the patients and the concentration and application mode of the drug were recorded. The changes in the signs and symptoms observed, and associated adverse effects, were then noted and analysed.

Results

The study population consisted of 11 patients, average age 10.5 years. All were treated with topical rapamycin, in six cases at 1%, in one at 0.8% and in four at 0.4%. Changes in the clinical appearance of the lesions were observed in all patients. The associated symptoms, present in 9 of the 11 patients, improved in every case. The mean follow-up time was 16.1 months.

Limitations

This study is retrospective, with a small sample size and considerable heterogeneity of lesions and treatment approaches.

Conclusions

Treatment with topical rapamycin modifies the clinical appearance and alleviates the symptoms of superficial LM.